MedTrace Logo

Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry

NCT02558205 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-10-08

No results posted yet for this study

Summary

The purpose of this study is to see if it is possible to establish a relationship between the blood flow and blood volume of liver tumors from CT body perfusion and the radiation dose deposited in the tumors from the radioembolization treatment as measured by PET/CT.

The study will do this by:

1. Measuring the blood flow and blood volume of tumors in the imaging data from a CT body perfusion
2. Measuring the radioactivity in the tumors after the radioembolization treatment using PET/CT and then calculating the dose deposited in the tumor
3. Using statistical analysis to assess the relationship between the dose and the perfusion parameters

In addition, the research may help develop a method for calculating the dose of radioembolization to be delivered to a liver tumor(s) using blood volume and blood flow data obtained from the CT body perfusion scans.

Conditions

Interventions

RADIATION

CT Liver Perfusion

Imaging study of liver using injection of Iodine contrast agent done using CT imaging

RADIATION

PET/CT of liver

PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.

Sponsors & Collaborators

  • Swim Across America

    collaborator OTHER

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Mark P Supanich, Ph.D. · Rush University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02558205 on ClinicalTrials.gov